1.60TWD
594.83 MTWD
5.14 BTWD
313.32 M
About SYNMOSA BIOPHARMA CORP
Sector
CEO
Chih Hui Lin
Headquarters
Taipei
Website
Founded
1970
ISIN
TW0004114004
FIGI
BBG000P5V247
Synmosa Biopharma Corp. engages in the manufacture and sale of ethical drug, over-the-counter drug, and healthcare products under Synmosa's trade mark. The firm's products include drugs for hormone replacement treatment, cardiovascular, neurology, urology, hormonal oncology, oral contraceptive, and over-the-counter products. It operates through the Active Pharmaceutical Ingredients and Generic Drugs segments. The company was founded on August 25, 1970 and is headquartered in Taipei, Taiwan.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of 4114 is 37.90 TWD — it has decreased by 2.07% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on TPEX exchange SYNMOSA BIOPHARMA CORP stocks are traded under the ticker 4114.
SYNMOSA BIOPHARMA CORP is going to release the next earnings report on May 29, 2024. Keep track of upcoming events with our Earnings Calendar.
4114 stock is 3.47% volatile and has beta coefficient of 0.04. Check out the list of the most volatile stocks — is SYNMOSA BIOPHARMA CORP there?
One year price forecast for SYNMOSA BIOPHARMA CORP has a max estimate of 43.00 TWD and a min estimate of 43.00 TWD.
4114 earnings for the last quarter are 0.32 TWD per share, whereas the estimation was 0.35 TWD resulting in a −10.26% surprise. The estimated earnings for the next quarter are 0.48 TWD per share. See more details about SYNMOSA BIOPHARMA CORP earnings.
SYNMOSA BIOPHARMA CORP revenue for the last quarter amounts to 1.11 B TWD despite the estimated figure of 1.10 B TWD. In the next quarter revenue is expected to reach 1.20 B TWD.
Yes, you can track SYNMOSA BIOPHARMA CORP financials in yearly and quarterly reports right on TradingView.
4114 stock has fallen by 4.05% compared to the previous week, the month change is a 3.19% fall, over the last year SYNMOSA BIOPHARMA CORP has showed a 7.77% decrease.
4114 net income for the last quarter is 170.70 M TWD, while the quarter before that showed 134.44 M TWD of net income which accounts for 26.97% change. Track more SYNMOSA BIOPHARMA CORP financial stats to get the full picture.
Today SYNMOSA BIOPHARMA CORP has the market capitalization of 14.79 B, it has increased by 0.13% over the last week.
Yes, 4114 dividends are paid annually. The last dividend per share was 0.56 TWD. As of today, Dividend Yield (TTM)% is 1.32%. Tracking SYNMOSA BIOPHARMA CORP dividends might help you take more informed decisions.
SYNMOSA BIOPHARMA CORP dividend yield was 1.55% in 2023, and payout ratio reached 37.24%. The year before the numbers were 1.15% and 22.89% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
Like other stocks, 4114 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade SYNMOSA BIOPHARMA CORP stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So SYNMOSA BIOPHARMA CORP technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating SYNMOSA BIOPHARMA CORP stock shows the buy signal. See more of SYNMOSA BIOPHARMA CORP technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on SYNMOSA BIOPHARMA CORP future price: according to them, 4114 price has a max estimate of 43.00 TWD and a min estimate of 43.00 TWD. Read a more detailed SYNMOSA BIOPHARMA CORP forecast: see what analysts think of SYNMOSA BIOPHARMA CORP and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. SYNMOSA BIOPHARMA CORP EBITDA is 955.58 M TWD, and current EBITDA margin is 18.59%. See more stats in SYNMOSA BIOPHARMA CORP financial statements.